



# Supplementary Materials: Amphiphilic Poly(*N*-Vinylpyrrolidone) Nanoparticles Conjugated with DR5-Specific Antitumor Cytokine DR5-B for Targeted Delivery to Cancer Cells


Anne Yagolovich, Andrey Kuskov, Pavel Kulikov, Leily Kurbanova, Dmitry Bagrov, Artem Artykov, Marine Gasparian, Svetlana Sizova, Vladimir Oleinikov, Anastasia Gileva, Mikhail Kirpichnikov, Dmitry Dolgikh and Elena Markvicheva



**Figure S1.** Expression and purification of DR5-B/V114C protein. Samples were analyzed in 14% Tris-glycine SDS-PAGE. Lanes: M—molecular weight markers; 1–20  $\mu$ L of cell culture after expression; 2—soluble cell fraction; 3–5—purified protein DR5-B/V114C.



**Figure S2.** DR5-B/V114C cytotoxic activity in human colorectal carcinoma HCT116 cell line. Cells were treated with ligands at the indicated concentrations for 24 h. Cell viability was determined by MTT test. Mean  $\pm$  Standard Deviation ( $n = 3$ ).



**Figure S3.** Morphology of 3D tumor spheroids of HCT116 colorectal carcinoma cells after 24 h incubation with P-DR5-B at concentration corresponding to 100 ng/mL of the DR5-B ligand.

**Table S1.** The values of standard errors of the regression (S) for IC<sub>50</sub> of free DR5-B and the P-DR5-B nanoparticles in 2D and 3D in vitro models.

	2D MCF-7		3D MCF-7		3D HCT116		3D HT29	
Incubation time, h	24	48	24	48	24	48	24	48
DR5-B	0.3577	0.4950	0.1552	0.1253	1.135	0.6893	0.2881	4.431
P-DR5-B	0.1202	0.2405	0.1937	0.1046	0.7644	0.4700	0.1712	0.2225